公开(公告)号：US20160264582A1

公开(公告)日：2016-09-15

申请号：US15069195

申请日：2016-03-14

Applicant: AbbVie Inc.

Inventor： Jerome Daanen ,  David DeGoey ,  Jennifer M. Frost ,  Tammie Jinkerson ,  Steve Latshaw ,  Lei Shi

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中GAr，L1，Z1和Z2如说明书中所定义，可用于治疗由电压门控钠通道预防或改善的病症或病症，例如Nav 1.7和/或Nav 1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US10266532B2

公开(公告)日：2019-04-23

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson ,  Jerome Daanen ,  Stevan Djuric ,  Amanda W. Dombrowski ,  Arthur Gomtsyan ,  Robert Schmidt

IPC: C07D521/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20130345255A1

公开(公告)日：2013-12-26

申请号：US13922442

申请日：2013-06-20

Applicant: AbbVie Inc.

Inventor： Arthur Gomtsyan ,  Jerome Daanen ,  Michael E. Kort ,  Philip R. Kym ,  Eric A. Voight ,  Kevin R. Woller

IPC: C07C317/28 ,  A61K31/192 ,  A61K31/353 ,  A61K31/436 ,  A61K31/352 ,  C07D311/96 ,  C07D491/052 ,  A61K31/18 ,  C07D311/68

CPC classification number: C07C317/28 ,  A61K31/18 ,  A61K31/192 ,  A61K31/352 ,  A61K31/353 ,  A61K31/436 ,  C07C311/08 ,  C07C2602/08 ,  C07D263/48 ,  C07D311/68 ,  C07D311/96 ,  C07D401/04 ,  C07D417/12 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US08796328B2

公开(公告)日：2014-08-05

申请号：US13922442

申请日：2013-06-20

Applicant: AbbVie Inc.

Inventor： Arthur Gomtsyan ,  Jerome Daanen ,  Michael E. Kort ,  Philip R. Kym ,  Eric A. Voight ,  Kevin R. Woller

IPC: A01N43/16 ,  A61K31/35

CPC classification number: C07C317/28 ,  A61K31/18 ,  A61K31/192 ,  A61K31/352 ,  A61K31/353 ,  A61K31/436 ,  C07C311/08 ,  C07C2602/08 ,  C07D263/48 ,  C07D311/68 ,  C07D311/96 ,  C07D401/04 ,  C07D417/12 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US09682985B2

公开(公告)日：2017-06-20

申请号：US15069195

申请日：2016-03-14

Applicant: AbbVie Inc.

Inventor： Jerome Daanen ,  David DeGoey ,  Jennifer M. Frost ,  Tammie Jinkerson ,  Steve Latshaw ,  Lei Shi

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160304517A1

公开(公告)日：2016-10-20

申请号：US15130362

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Jerome Daanen ,  Justin Dietrich ,  Stevan Djuric ,  Amanda W. Dombrowski ,  Kristine E. Frank ,  Michael M. Friedman ,  Arthur Gomtsyan ,  Huan-Qui Li ,  Kenton Longenecker ,  Augustine Osuma ,  Ann Marie Rowley ,  Robert Schmidt ,  Anil Vasudevan ,  Noel Wilson

IPC: C07D471/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D471/18 ,  C07D471/14 ,  C07D498/22 ,  C07D498/14 ,  C07D498/20 ,  C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供三环杂环化合物，药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。